Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat

Virchows Archiv

Volumn 450, Issue 3, 2007, Pages 335-341

  Mucha, Slawomir A ^a   Meleń Mucha, Gabriela ^a   Godlewski, Andrzej ^a   Stepień, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Angiogenesis; Apoptosis; Pituitary; Prolactinoma; Proliferation

Indexed keywords

BATIMASTAT; CD31 ANTIGEN; DIETHYLSTILBESTROL; ESTROGEN; METALLOPROTEINASE INHIBITOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FISCHER 344 RAT; HYPOPHYSIS TUMOR; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROLACTINOMA; RAT; SILASTIC TUBE; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; DIETHYLSTILBESTROL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; ESTROGENS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; METALLOENDOPEPTIDASES; NEOVASCULARIZATION, PATHOLOGIC; ORGAN SIZE; PHENYLALANINE; PITUITARY GLAND, ANTERIOR; PITUITARY NEOPLASMS; PROLACTINOMA; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEASE INHIBITORS; RATS; RATS, INBRED F344; THIOPHENES;

EID: 33847704172     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-006-0351-x     Document Type: Article

References (47)

1. Asa SL, Ezzat S (1998) The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19:798-827
2. Beaulieu E, Kachra Z, Mousseau N, Delbecchi L, Hardy J, Beliveau R (1999) Matrix metalloproteinases and their inhibitors in human pituitary tumors. Neurosurgery 45:1432-1441
3. Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220-240
4. Bravo R, Frank R, Blundell PA, MacDonald-Bravo H (1987) Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ. Nature 326:515-517
5. Brown PD, Giavazzi R (1995) Matrix metalloproteinase inhibition - a review of anti-tumor activity. Ann Oncol 6:967-974
6. Chirivi RGS, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciano A, Brown PD, Giavazzi R (1994) Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460-464
7. Davies B, Brown P, East N, Crimmin MJ, Balkwill FR (1993) A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087-2091. Erratum: Cancer Res 53:3652
8. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Albelda SM (1997) Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151:671-677
9. Elias KA, Weiner RI (1984) Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors. Proc Natl Acad Sci USA 81:4549-4553
10. Farnoud MR, Farhadian F, Samuel JL, Derome P, Peillon F, Li JY (1995) Fibronectin isoforms are differentially expressed in normal and adenomatous human anterior pituitaries. Int J Cancer 61:27-34
11. Farnoud MR, Veirana N, Derome P, Peillon F, Li JY (1996) Adenomatous transformation of the human anterior pituitary is associated with alterations in integrin expression. Int J Cancer 67:45-53
12. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
13. Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL (1999) Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59:5356-5364
14. Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501
15. Heath EI, Grochow LB (2000) Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 59:1043-1055
16. Jugenburg M, Kovacs K, Jugenburg I, Scheithauer BW (1998) Angiogenesis in endocrine neoplasms. Endocr Pathol 8:259-272
17. Katznelson L, Alexander JM, Klibanski A (1993) Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 76:1089-1094
18. Knox JD, Bretton L, Lynch T, Bowden GT, Nagle RB (1998) Synthetic matrix metalloproteinase inhibitor, BB-94, inhibits the invasion of neoplastic human prostate cells in a mouse model. Prostate 35:248-254
19. Lei H, Kalluri R, Furth EE, Baker AH, Strauss JF 3rd (1999) Rat amnion type IV collagen composition and metabolism: implications for membrane breakdown. Biol Reprod 60:176-182
20. Lein M, Jung K, Le DK, Hasan T, Ortel B, Borchert D, Winkelmann B, Schnorr D, Loenings SA (2000) Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate 43:77-82
21. Levy A (1999) Mitosis and apoptosis in anterior pituitary gland: tumour formation or hyperplasia? Baillieres Best Pract Res Clin Endocrinol Metab 13:353-365
22. Meleń-Mucha G, Winczyk K, Pawlikowski M (1998) Somatostatin analogue octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplantable murine colon 38 cancer. Anticancer Res 18:3615-3620
23. Minderman T, Wilson CB (1994) Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol 41:359-364
24. Murphy G, Docherty AJP (1992) The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 7:120-125
25. Páez Pereda M, Ledda MF, Goldberg V, Chervin A, Carrizo G, Molina H, Müller A, Renner U, Podhajcer O, Arzt E, Stalla GK (2000) High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. J Clin Endocrinol Metab 85:263-269
26. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500-509
27. Pereda MP, Goldberg V, Chervin A, Carizzo G, Molina A, Andrada J, Sauer J, Renner U, Stalla GK, Arzt E (1996) Interleukin-2 (IL-2) and IL-6 regulate c-fos protooncogene expression in human pituitary adenoma explants. Mol Cell Endocrinol 124:33-42
28. Phelps C, Hymer WC (1983) Characterization of oestrogen-induced adenohypophyseal tumors in the Fischer 344 rat. Neuroendocrinology 37:23-31
29. Sang QX (1998) Complex role of matrix metalloproteinases in angiogenesis. Cell Res 8:171-177
30. Schechter J, Ahmad N, Elias K, Weiner R (1987) Estrogen-induced tumors: changes in the vasculature in two strains of rat. Am J Anat 179:315-323
31. Scheithauer BW, Kovacs KT, Laws ER, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65:733-744
32. Sledge GW Jr, Qulali M, Goulet R, Bone EA, Fife R (1995) Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87:1546-1550
33. Spady TJ, McComb RD, Shull JD (1999) Estrogen action in the regulation of cell proliferation, cell survival, and tumorigenesis in the rat anterior pituitary gland. Endocrine 11:217-233
34. Stefaneanu L, Kovacs K, Scheithauer BW, Kontogeorgos G, Riehle DL, Sebo TJ, Murray D, Vidal S, Tran A, Buchfelder M, Fahlbusch R (2000) Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocr Pathol 11:341-352
35. Stepień H, Grochal M, Zieliński KW, Mucha S, Kunert-Radek J, Kulig A, Stawowy A, Pisarek H (1996) Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. J Endocrinol 150:99-106
36. Talbot DC, Brown PD (1996) Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32:2528-2533
37. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, Giavazzi R (1995) Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87:293-298
38. Turner HE, Nagy Z, Esiri MM, Harris AL, Wass JAH (2000) Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab 85:2931-2935
39. Turner HE (2001) Pituitary tumor angiogenesis. Endocrinologist 11:465-469
40. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM (1994) Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726-4728
41. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 324:1-8
42. Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169-180
43. Wiklund J, Wertz N, Gorski J (1981) A comparison of estrogen effects on uterine and pituitary growth and prolactin synthesis in F344 and Holtzman rats. Endocrinology 109:1700-1707
44. Woessner JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145-2154
45. Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A, Hawkins MJ (1996) Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 14:193-202
46. Wyllie AH (1993) Apoptosis (The 1992 Frank Rose Memorial Lecture). Br J Cancer 67:205-208
47. Zervos EE, Norman JG, Gower WR, Franz MG, Rosemurgy AS (1997) Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J Surg Res 69:367-371